Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
WYSZOMIERSKI JACK L | Director | Jun 04 '24 | Sale | 22.00 | 8,287 | 182,314 | 349,499 | Jun 06 08:37 PM | JOHNSON DAVID EDWARD | Director | May 30 '24 | Buy | 20.76 | 225,000 | 4,670,055 | 1,525,730 | May 30 07:50 PM | JOHNSON DAVID EDWARD | Director | May 28 '24 | Buy | 20.32 | 200,000 | 4,063,900 | 1,300,730 | May 30 07:50 PM | POSTE GEORGE | Director | May 21 '24 | Option Exercise | 19.57 | 11,686 | 228,695 | 225,593 | May 22 07:23 PM | Smith Julie | Director | May 21 '24 | Sale | 21.12 | 27,280 | 576,154 | 5,445 | May 23 06:55 PM | POSTE GEORGE | Director | May 21 '24 | Sale | 20.96 | 11,686 | 244,939 | 213,907 | May 22 07:23 PM | PAPADOPOULOS STELIOS | Director | May 20 '24 | Option Exercise | 19.57 | 11,686 | 228,695 | 1,272,015 | May 22 07:23 PM | PAPADOPOULOS STELIOS | Director | May 20 '24 | Sale | 21.00 | 11,437 | 240,177 | 1,260,578 | May 22 07:23 PM | WYSZOMIERSKI JACK L | Director | May 13 '24 | Option Exercise | 19.57 | 11,686 | 228,695 | 349,871 | May 15 07:44 PM | WYSZOMIERSKI JACK L | Director | May 13 '24 | Sale | 21.37 | 10,923 | 233,425 | 338,948 | May 15 07:44 PM | Garber Alan M | Director | Mar 21 '24 | Option Exercise | 19.57 | 23,491 | 459,719 | 54,908 | Mar 25 07:31 PM | Garber Alan M | Director | Mar 21 '24 | Sale | 24.01 | 19,205 | 461,112 | 35,703 | Mar 25 07:31 PM | Haley Patrick J. | EVP, Commercial | Feb 23 '24 | Sale | 21.45 | 47,020 | 1,008,579 | 384,866 | Feb 27 06:58 PM | JOHNSON DAVID EDWARD | Director | Feb 21 '24 | Buy | 20.70 | 190,000 | 3,932,734 | 1,100,730 | Feb 22 05:08 PM | Haley Patrick J. | EVP, Commercial | Dec 14 '23 | Option Exercise | 16.29 | 50,000 | 814,500 | 357,687 | Dec 14 07:56 PM | Haley Patrick J. | EVP, Commercial | Dec 14 '23 | Sale | 23.35 | 50,000 | 1,167,500 | 307,687 | Dec 14 07:56 PM | Hessekiel Jeffrey | EVP, General Counsel & Sec | Dec 13 '23 | Sale | 23.01 | 25,000 | 575,250 | 533,345 | Dec 14 07:55 PM | Haley Patrick J. | EVP, Commercial | Dec 12 '23 | Sale | 22.50 | 14,149 | 318,352 | 307,687 | Dec 14 07:56 PM | Hessekiel Jeffrey | EVP, General Counsel & Sec | Dec 04 '23 | Sale | 22.06 | 25,000 | 551,500 | 558,345 | Dec 04 06:22 PM | Hessekiel Jeffrey | EVP, General Counsel & Sec | Nov 30 '23 | Sale | 22.01 | 25,000 | 550,250 | 583,345 | Dec 04 06:22 PM | JOHNSON DAVID EDWARD | Director | Nov 27 '23 | Buy | 21.61 | 120,409 | 2,602,038 | 910,730 | Nov 29 04:30 PM | JOHNSON DAVID EDWARD | Director | Nov 27 '23 | Sale | 21.61 | 120,409 | 2,602,038 | 790,321 | Nov 29 04:30 PM | Aftab Dana | CSO/EVP Disc & Trans Research | Aug 30 '23 | Sale | 22.47 | 4,600 | 103,362 | 399,943 | Sep 01 08:15 PM | MORRISSEY MICHAEL | President and CEO | Aug 28 '23 | Option Exercise | 15.31 | 360,000 | 5,511,600 | 945,496 | Aug 30 09:48 PM | Senner Christopher J. | EVP and CFO | Aug 04 '23 | Option Exercise | 14.74 | 60,000 | 884,400 | 631,631 | Aug 07 09:20 PM | Senner Christopher J. | EVP and CFO | Aug 04 '23 | Sale | 20.68 | 60,000 | 1,240,800 | 571,631 | Aug 07 09:20 PM | Senner Christopher J. | EVP and CFO | Aug 03 '23 | Option Exercise | 14.74 | 60,000 | 884,400 | 631,631 | Aug 07 09:20 PM | Senner Christopher J. | EVP and CFO | Aug 03 '23 | Sale | 20.51 | 60,000 | 1,230,600 | 571,631 | Aug 07 09:20 PM | Haley Patrick J. | EVP, Commercial | Aug 03 '23 | Sale | 20.67 | 30,553 | 631,531 | 285,467 | Aug 07 08:24 PM | Hessekiel Jeffrey | EVP, General Counsel & Sec | Aug 01 '23 | Option Exercise | 14.74 | 55,710 | 821,165 | 627,686 | Aug 03 08:02 PM | Hessekiel Jeffrey | EVP, General Counsel & Sec | Aug 01 '23 | Sale | 19.63 | 55,710 | 1,093,587 | 571,976 | Aug 03 08:02 PM |
|